MSLN and cervical carcinoma: While these results demonstrated strong specificity of the CAR-NK-92 cells to target Mesothelin-expressing cervical cancer cells, this data also suggest the presence of immune evasion mechanisms that lead to resistance of these tumor models to NK-92 and CAR-NK-92 cell therapy.